CNI Second Opinion™ Prostate Cancer Evaluation Test

It has recently been found that mutated DNA fragments from cancer cells find their way into the bloodstream. They can be detected by next generation sequencing – the technique that has successfully mapped the whole human genome. Prostate cancer mutations tend to produce “hot spots” (gains and losses) in the mutated DNA fragments that are in the blood. The reasons are currently under investigation. Nonetheless, DNA from the cancer cells is detectable in your bloodstream. The Chronix Second Opinion™ prostate cancer evaluation searches for these sequences and identifies them.  Chronix currently is conducting clinical trails on its 2nd Opinion Prostate Cancer tests.

CNI Second Opinion™ Breast Cancer Evaluation Test

Chronix Biomedical has made available a laboratory developed test for the detection of risk factors highly associated with Breast cancer. Through the simple process of drawing blood, we can now offer a test than can with a high degree of accuracy, detect macromolecular mutations of DNA fragments in blood plasma, which are closely associated with Breast cancer. The Chronix Biomedical Second Opinion™ Breast Cancer Evaluation blood test was designed to be a supplemental test for women with abnormal mammograms or detectable lumps.


Patient Consent

Please note, that Chronix tests are known as „Laboratory developed tests” that doctors use to help make medical decisions. There is a Chance of false positive and false negative results. A patient taking blood sample of our tests must be aware of this statement and sign a Consent Form.

Different outcome scenarios as result of the CNI score